Preview

Rational Pharmacotherapy in Cardiology

Advanced search

HIGH VERSUS STANDARD CLOPIDOGREL MAINTENANCE DOSE AFTER PERCUTANEOUS CORONARY INTERVENTION AND EFFECTS ON PLATELET INHIBITION, ENDOTHELIAL FUNCTION, AND INFLAMMATION. RESULTS OF THE ARMYDA-150 MG (ANTIPLATELET THERAPY FOR REDUCTION OF MYOCARDIAL DAMAGE DURING ANGIOPLASTY) RANDOMIZED STUDY

https://doi.org/10.20996/1819-6446-2011-7-5-644-652

Full Text:

About the Authors

G. Patti

Russian Federation


D. Grieco

Russian Federation


G. Dicuonzo

Russian Federation


V. Pasceri

Russian Federation


A. Nusca

Russian Federation


G. Sciascio

Russian Federation


References

1. Yusuf S., Zhao F., Mehta SR., Chrolavicius S., Tognoni G., Fox K.K. for the Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494 –502.

2. Mehta S.R., Yusuf S., Peters R.J. et al., for the Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial (CURE) Investigators. Effects of pre-treatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:527–33.

3. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Guidelines for percutaneous coronary interventions. Eur Heart J 2005;26:804–47.

4. Gurbel P.A., Bliden K.P., Hiatt B.L. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pre-treatment platelet reactivity. Circulation 2003;107:2908 –13.

5. Patti G., Nusca A., Mangiacapra F., Gatto L., D’Ambrosio A., Di Sciascio G. Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention. Results of the ARMYDA-PRO (Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty— Platelet Reactivity Predicts Outcome) study. J Am Coll Cardiol 2008;52: 1128 –33.

6. Buonamici P., Marcucci R., Migliorini A. et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 2007;49:2312–7.

7. Price M.J., Endemann S., Gollapudi R.R. et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 2008;29:992–1000.

8. Bliden K.P., DiChiara J., Tantry U.S., Bassi A.K., Chaganti S.K., Gurbel P.A. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention. J Am Coll Cardiol 2007;49:657– 66.

9. Hochholzer W., Trenk D., Bestehorn H.P. et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 2006;48:1742–50.

10. Kastrati A., von Beckerath N., Joost A., Pogatsa-Murray G., Gorchakova O., Schömig A. Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy. Circulation 2004;110:1916 –9.

11. Von Beckerath N., Kastrati A., Wieczorek A. et al. A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days. Eur Heart J 2007;28:1814 –9.

12. Lemesle G., Delhaye C., Sudre A. et al. Impact of high loading and maintenance dose of clopidogrel within the first 15 days after percutaneous coronary intervention on patient outcome. Am Heart J 2009;157:375– 82.

13. Vivekananthan D.P., Bhatt D.L., Chew D.P. et al. Effect of clopidogrel pretreatment on periprocedural rise in C-reactive protein after percutaneous coronary intervention. Am J Cardiol 2004;94:358–60.

14. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E. et al. Clopidogrel withdrawal is associated with proinflammatory and prothrombotic effects in patients with diabetes and coronary artery disease. Diabetes 2006;55:780–4.

15. Warnholtz A., Ostad M.A., Velich N. et al. A single loading dose of clopidogrel causes dose-dependent improvement of endothelial dysfunction in patients with stable coronary artery disease: results of a double-blind, randomized study. Atherosclerosis 2008;196:689 –95.

16. Patti G., Colonna G., Pasceri V., Lassandro-Pepe L., Montinaro A., Di Sciascio G. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty) study. Circulation 2005;111:2099 –106.

17. Lau W.C., Waskell L.A., Watkins P.B. et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation 2003;107:32–7.

18. Gilard M., Arnaud B., Cornily J.C. et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole Clopidogrel Aspirin) study. J Am Coll Cardiol 2008;51:256–60.

19. Malinin A., Pokov A., Spergling M. et al. Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12 rapid analyzer: the Verify Thrombosis Risk Assessment (VERITAS) study. Thromb Res 2007;119:277– 84.

20. Mangiacapra F., Barbato E., Patti G. et al. Point-of-care assessment of platelet reactivity after clopidogrel to predict myonecrosis in patients undergoing percutaneous coronary intervention. J Am Coll Cardiol Intv 2010;3:318 –23.

21. Marcucci R., Gori A.M., Paniccia R. et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation 2009;119:237– 42.

22. El-Tamimi H., Mansour M., Pepine C.J., Wargovich T.J., Chen H. Circadian variation in coronary tone in patients with stable angina. Protective role of the endothelium. Circulation 1995;92:3201–5.

23. Patti G., Pasceri V., Melfi R. et al. Impaired flow-mediated dilation and risk of restenosis in patients undergoing coronary stent implantation. Circulation 2005;111:70 –5.

24. Centers for Disease Control/American Heart Association Workshop on Inflammatory Markers, and Cardiovascular Disease. Application to Clinical and Public Health Practice: Atlanta, March 14–15, 2002. Atlanta, Georgia: Centers for Disease Control and Prevention, 2002.

25. Aleil B., Jacquemin L., De Poli F. et al. Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (Vasodila-tor-Stimulated Phosphoprotein-02) randomized study. J Am Coll Cardiol Intv 2008;1:631– 8.

26. Sharis P.J., Cannon C.P., Loscalzo J. The antiplatelet effects of ticlopidine and clopidogrel. Ann Intern Med 1998;129:394–405.

27. Palmerini T., Barozzi C., Tomasi L. et al. A randomised study comparing the antiplatelet and antinflammatory effect of clopidogrel 150 mg/day versus 75 mg/day in patients with ST-segment elevation acute myocardial infarction and poor responsiveness to clopidogrel: results from the DOUBLE study. Thromb Res 2010; 125:309 –14.

28. Angiolillo D.J., Bernardo E., Palazuelos J. et al. Functional impact of high clopidogrel maintenance dosing in patients undergoing elective percutaneous coronary interventions. Results of a randomized study. Thromb Haemost 2008;99:161– 8.

29. Angiolillo D.J., Shoemaker S.B., Desai B. et al. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation 2007;115:708 –16.

30. Fontana P., Senouf D., Mach F. Biological effect of increased maintenance dose of clopidogrel in cardiovascular outpatients and influence of the cytochrome P450 2C19*2 allele on clopidogrel responsiveness. Thromb Res 2008;121:463– 8.

31. Jakubowski A., Chlopicki S., Olszanecki R. et al. Endothelial action of thienopyridines and thienopyrimidinones in the isolated guinea pig heart. Prostagland Leukot Essent Fatty Acids 2005;72:139–45.

32. Shanker G., Kontos J.L., Eckman D.M., Wesley-Farrington D., Sane D.C. Nicotine upregulates the expression of P2Y12 on vascular cells and megakaryoblasts. J Thromb Thrombolysis 2006;22:213–20.

33. Azar R.R., Kassab R., Zoghbi A. et al. Effects of clopidogrel on soluble CD40 ligand and on high-sensitivity C-reactive protein in patients with stable coronary artery disease. Am Heart J 2006;151:521.e1– 4.

34. Bhatt D.L., Fox K.A., Hacke W. et al., for the CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006;354:1706 –17.

35. Buffon A., Liuzzo G., Biasucci L.M. et al. Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty. J Am Coll Cardiol 1999;34:1512–21.

36. The CURRENT-OASIS 7 Investigators. Dose comparison of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med 2010;363:930–42.


For citation:


Patti G., Grieco D., Dicuonzo G., Pasceri V., Nusca A., Sciascio G. HIGH VERSUS STANDARD CLOPIDOGREL MAINTENANCE DOSE AFTER PERCUTANEOUS CORONARY INTERVENTION AND EFFECTS ON PLATELET INHIBITION, ENDOTHELIAL FUNCTION, AND INFLAMMATION. RESULTS OF THE ARMYDA-150 MG (ANTIPLATELET THERAPY FOR REDUCTION OF MYOCARDIAL DAMAGE DURING ANGIOPLASTY) RANDOMIZED STUDY. Rational Pharmacotherapy in Cardiology. 2011;7(5):644-652. (In Russ.) https://doi.org/10.20996/1819-6446-2011-7-5-644-652

Views: 285


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)